Inflammatory Markers in Lumbar Radicular Pain Treated With PRF and TFESI
CompletedNCT07495566
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This retrospective observational study aims to evaluate the predictive value of systemic inflammatory markers in determining treatment response in patients with lumbar radicular pain treated with a combination of pulsed radiofrequency (PRF) and transforaminal epidural steroid injection (TFESI). Hematologic indices derived from routine blood tests-including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), platelet-to-neutrophil ratio (PNR), neutrophil-to-monocyte ratio (NMR), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), mean platelet volume (MPV), red cell distribution width-standard deviation (RDW-SD), and red cell distribution width-coefficient of variation (RDW-CV) and pain scores assessed using the Numeric Rating Scale (NRS), will be analyzed in relation to treatment success (defined as ≥50% NRS reduction at 4 weeks). Receiver operating characteristic (ROC) analysis will be used to determine optimal cutoff values for significant markers. The study aims to contribute to personalized pain management strategies by identifying accessible biomarkers that may predict treatment outcomes.
Study details
- Official title
- The Predictive Value of Systemic Inflammatory Markers in Treatment Response in Lumbar Radicular Pain Treated With Pulsed Radiofrequency and Transforaminal Epidural Steroid Injection
- Conditions
- Inflammatory Response
- Radiculopathy
- Radiculopathy Lumbar
- Chronic Pain
- Interventions
- Procedure: Lumbar Dorsal Root Ganglion Pulsed Radiofrequency
- Sponsor
- Ankara Etlik City Hospital
- Start date
- 2025-12-30
- Primary completion
- 2026-01-15
- Sex
- All
- Age range
- from 18 Years to 85 Years
- Results posted
- No results posted in this snapshot
- Countries
- Turkey (Türkiye)
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Age between 18 and 85 years. * Clinically and radiologically confirmed diagnosis of lumbar radiculopathy. * Underwent pulsed radiofrequency (PRF) and transforaminal epidural steroid injection (TFESI) targeting the same dorsal root ganglion (DRG) in a single session. * Availability of pre-intervention laboratory data, including: Complete blood count (CBC) * Documented Numeric Rating Scale (NRS) scores before and 4 weeks after the intervention. * Medical records complete for demographic, clinical, and laboratory variables. Exclusion Criteria: * History of prior lumbar spine surgery. * Presence of systemic inflammatory, autoimmune, or hematological diseases. * Diagnosis of malignancy. * Active infection at the time of procedure. * Use of systemic corticosteroids or immunosuppressive agents within the last 4 weeks. * Incomplete clinical or laboratory data. * Patients outside the age range (under 18 or over 85)
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07495566